Abstract
SARS-CoV-2 infection induces a coagulopathy characterized by platelet activation and a hypercoagulable state with an increased incidence of cardiovascular events. The viral spike protein S has been reported to enhance thrombosis formation, stimulate platelets to release pro-coagulant factors and promote the formation of platelet-leukocyte aggregates even in absence of the virus. Although SARS-CoV-2 vaccines induce spike protein overexpression to trigger SARS-CoV-2-specific immune protection, thrombocyte activity has not been investigated in this context. Here, we provide the first phenotypic platelet characterization of healthy human subjects undergoing BNT162b2 vaccination.
Using mass cytometry, we analyzed the expression of constitutive transmembrane receptors, adhesion proteins and platelet activation markers in 12 healthy donors before and at five different timepoints within four weeks after the first BNT162b2 administration. We measured platelet reactivity by stimulating thrombocyte activation with thrombin receptor-activating peptide (TRAP). Activation marker expression (P-Selectin, LAMP-3, LAMP-1, CD40L and PAC-1) did not change after vaccination. All investigated constitutive transmembrane proteins showed similar expressions over time. Platelet reactivity was not altered after BNT162b2 administration. Activation marker expression was significantly lower compared to an independent cohort of mild symptomatic COVID-19 patients analyzed with the same platform.
This study reveals that BNT162b2 administration does not alter platelet protein expression and reactivity.
Competing Interest Statement
The authors declare that they have no conflict of interest, except CDS. Christoph Spinner reports grants, personal fees, non-financial support and other from AbbVie, grants, personal fees, non-financial support and other from Apeiron, personal fees from Formycon, grants, personal fees, non-financial support and other from Gilead Sciences, grants, personal fees and other from Eli Lilly, grants, personal fees, non-financial support and other from Janssen-Cilag, grants, personal fees, non-financial support and other from GSK/ViiV Healthcare, grants, personal fees, non-financial support and other from MSD, outside the submitted work.
Funding Statement
This work was supported by the German Center for Cardiovascular Research (DZHK grant number 81X3600606 to D.B.). J.B. and M.L. are grateful for financial support from BMBF grant Sys_CARE [grant number01ZX1908A] of the Federal German Ministry of Research and Education. The work of O.L. was funded by the Bavarian State Ministry of Science and the Arts as part of the Bavarian Research Institute for Digital Transformation (bidt).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committee of the Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany (approval number 4/21 S-KH) by chairman Prof. Dr. Georg Schmidt. Ethical approval was given in a letter written on the 03.01.2021 after a consultation of the commitee according to paragraph 15 of the professional regulations for doctors in bavaria (Berufsordnung fuer Aerzte in Bayern). The ethics agreement also contained a consent form which was signed by all participants of the study. In addition to that the study complies to the Declaration of Helsinki of the world medical association (WMA) which is a as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† these authors are joint senior author
Data Availability
All mass cytometry data and FlowSOM results have been made available at flowrepository.org and can be accessed at repository ID FR-FCM-Z3XS. The scripts used in this analysis have been deposited at github.com and can be accessed at https://github.com/biomedbigdata/Platelet-activation-after-vaccine-administration.
https://flowrepository.org/id/FR-FCM-Z3XS
https://github.com/biomedbigdata/Platelet-activation-after-vaccine-administration
